AbbVie tries a new approach in 340B programme battle
AbbVie has opened a new front in the pharma industry's efforts to reform the 340B drug discounting programme for safety net hospitals in the US.
Newsletters and Deep Dive digital magazine
AbbVie has opened a new front in the pharma industry's efforts to reform the 340B drug discounting programme for safety net hospitals in the US.
The impact of the geopolitical disruption is starting to tell on global supply chains for medicines and key chemicals for the pharmaceutical industry.
Shah Capital has fired another broadside at vaccine firm Novavax, accusing its board and management of a "destruction in shareholder value."
Neurocrine Biosciences has agreed a $2.9bn deal to buy Soleno Therapeutics and its treatment for a rare, genetic form of severe obesity.
Trump signs his pharma tariffs executive order, which won't affect most large pharma groups but could deal a hefty blow to smaller companies.
Editor's Picks
Newsletters and Deep Dive
digital magazine